Breast cancer pharmacogenomics: Why local genetic data matters for African patients

The Problem: Breast cancer pharmacogenomics

Doctors need the right intelligence to fight cancer. Currently, treatments rely on genetic data gathered mostly from European and Asian patients. Breast cancer pharmacogenomics studies how a person's genes affect their response to cancer drugs. However, this field has a massive blind spot. In Sudan and across Africa, genetic diversity is incredibly high. Patients often receive treatments based on foreign genetic profiles. This mismatch means drugs might not work as intended. They could even cause severe side effects. The bottom line is clear. We need local data to treat local patients effectively.

The Solution: Gathering local intelligence

A recent review synthesised existing evidence on genetic factors that influence cancer treatments. Researchers focused on African and Sudanese populations. They looked at studies published between 2005 and 2026. The goal was to map the specific genetic variations that change how bodies process medication. By identifying these local genetic markers, doctors could eventually tailor treatments to the individual. This approach aims to maximise drug effectiveness while minimising harmful toxicity.

The Mechanism: How genes process drugs

Your body uses specific proteins to break down medicines. The review measured interethnic variability in several key genes, such as CYP2D6 and CYP3A4. These genes act like chemical factories. They metabolise drugs and transport them through the body. African populations exhibit distinct patterns in these genes. Because of these differences, a standard dose of chemotherapy or hormone therapy might be processed too quickly or too slowly. If processed too quickly, the drug leaves the body before it can destroy the tumour. If processed too slowly, the drug builds up and causes dangerous toxicity. The study suggests that directly applying foreign genetic data to African patients ignores these vital biological differences.

The Impact: Building a safer future

This research exposes a major gap in global oncology. Precision medicine should benefit everyone, not just specific demographics. Integrating genetic insights into clinical practice could significantly improve survival rates in Sudan. However, achieving this requires investment. Hospitals need better diagnostic tools. Laboratories must expand their testing programmes. The review suggests a stepwise approach to bringing these genetic principles into everyday clinical use. Ultimately, generating local data is the only way to ensure safe, equitable, and effective cancer care for African populations.